Day: November 3, 2022

On March 27, 2020, Shi, Jinping; Wang, Jiaqin published a patent.Product Details of 23256-42-0 The title of the patent was A method for preparing doxycycline soluble powder for veterinary medicine. And the patent contained the following:

This article discloses about a method for preparing doxycycline soluble powder for veterinary medicine. The veterinary doxycycline soluble powder medicine is composed of doxycycline, trimethoprim lactate and anhydrous glucose. In the present invention, doxycycline, trimethoprim lactate and anhydrous glucose are resp. crushed and sieved; the sieved doxycycline and trimethoprim lactate are weighed and added to the weight of the two components. Premix with the same amount of anhydrous glucose according to the dispersion method, then add the remaining amount of anhydrous glucose to fully mix, after mixing, crush and sieve again to obtain the finished product. The veterinary doxycycline soluble powder has good drug effect, quick effect, convenient use, simple and easy preparation method, low cost, convenient large-scale industrial production, and promotion and application. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to doxycycline trimethoprim lactate glucose solubility pharmaceutical powder veterinary medicine, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 10, 1975, Holstius, Elvin A.; Alvan, George E. published a patent.Application of 23256-42-0 The title of the patent was Antibacterial, pharmaceutical ear and eye formulations. And the patent contained the following:

An aqueous solution or an ointment, containing sulfacetamide (I) [144-80-9] 0.1-0.5 trimethoprim hemisulfate (II) [56585-33-2] 0.1-0.5, and polymyxin 0.05-0.15 weight/volume %, was stable and possessed a wide spectrum of antibacterial activity. In an example, 100 ml aqueous solution contained 0.50 I, II corresponding to 0.10 g trimethoprim free base, 0.15 polymyxin B sulfate [1405-20-5] 0.001 thiomersal, and 0.83 g NaCl. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application of 23256-42-0

The Article related to bactericide ear eye, sulfacetamide bactericide ear eye, trimethoprim bactericide ear eye, polymixin bactericide ear eye, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On February 21, 2007, Yang, Jianbin published a patent.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Antibacterial compositions containing combination of florfenicol and tiamulin and doxycycline hydrochloride and trimethoprim lactate for treating mycoplasma and other bacterial infections in chicken and pig. And the patent contained the following:

The title drug is composed of (by weight parts) florfenicol 5-15, tiamulin fumarate 5-15, doxycycline hydrochloride 5-15, trimethoprim lactate 5-10 and excipient. The drug is used for treating mixed mycoplasma and other bacteria infection of chicken and pig. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to combination chemotherapy antibacterial chicken pig, florfenicol tiamulin doxycycline hydrochloride trimethoprim lactate, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 1, 2009, Wu, Hongyun; Li, Jianzheng; Wang, Xiuhua published a patent.Application In Synthesis of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Veterinary composition containing chinese medicines and ceftiofur for treating avian bacterial and/or viral diseases. And the patent contained the following:

The title veterinary drug contains honeysuckle 300-400, Scutellaria baicalensis 300-400, Forsythia suspensa 700-800, ceftiofur 0.5-1.5, synergists 0.5-1, antibacterial factor 20-30, and lytic factor 5-15 weight part. The synergists contain trimethoprim lactate and sulbactam sodium at ratio of 1: (0.5-1). The antibacterial factor is Pirarubicin hydrochloride. The lytic factor is mixture of N-Me pyrrolidone, propanediol, and water for injection at weight ratio of 1:1:1. The preparation method comprises of (1) decocting Scutellaria baicalensis with water three times, combining decoction liquid, filtering, concentrating filtrate, adjusting pH to 1.0-2.0 with 2 mol/L HCl at 75-80°, keeping temperature for 30 min, standing for 10-13 h, filtering, stirring sediment with 6-8 fold water, adjusting pH to 7.0 with NaOH, adding ethanol, dissolving by stirring, filtering, adjusting filtrate pH to 1.5-2 with HCl, keeping at 55-65° for 30 min, standing for 10-13 h, filtering, washing sediment with ethanol, adjusting pH to 7.0, reclaiming ethanol; processing honeysuckle and Forsythia suspensa with same methods, mixing with above Scutellaria baicalensis extract, adding water, adjusting pH to 7.0 with NaOH, stirring, preserving at 4-8° for 72 h, filtering, and adjusting filtrate pH to 7.0 to obtain solution A for further use. The preparation method also comprises (2) mixing antibacterial factor with solution A under stirring at 500 r/min, filling, sterilizing at 100° for 30 min; (3) dissolving synergists with lytic factor, filling, sterilizing at 100° for 30 min; (4) adding ceftiofur, and split charging to obtain. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Application In Synthesis of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to chinese medicine veterinary drug avian lonicera scutellaria forsythia, antiviral agent antibiotic ceftiofur pirarubicin, Pharmaceuticals: Formulation and Compounding and other aspects.Application In Synthesis of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 7, 2021, Weng, Guorong; Vlcek, VojtEch published an article.Recommanded Product: 65-71-4 The title of the article was Efficient treatment of molecular excitations in the liquid phase environment via stochastic many-body theory. And the article contained the following:

Accurate predictions of charge excitation energies of mols. in the disordered condensed phase are central to the chem. reactivity, stability, and optoelectronic properties of mols. and critically depend on the specific environment. Herein, we develop a stochastic GW method for calculating these charge excitation energies. The approach employs maximally localized electronic states to define the electronic subspace of a mol. and the rest of the system, both of which are randomly sampled. We test the method on three solute-solvent systems: phenol, thymine, and phenylalanine in water. The results are in excellent agreement with the previous high-level calculations and available exptl. data. The stochastic calculations for supercells containing up to 1000 electrons representing the solvated systems are inexpensive and require ≤1000 central processing unit hrs. We find that the coupling with the environment accounts for ∼ 40% of the total correlation energy. The solvent-to-solute feedback mechanism incorporated in the mol. correlation term causes up to 0.6 eV destabilization of the quasiparticle energy. Simulated photoemission spectra exhibit red shifts, state-degeneracy lifting, and lifetime shortening. Our method provides an efficient approach for an accurate study of excitations of large mols. in realistic condensed phase environments. (c) 2021 American Institute of Physics. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Recommanded Product: 65-71-4

The Article related to excitation mol liquid medium stochastic many body gw method, phenol thymine phenylalanine water solvent excitation stochastic gw method, General Physical Chemistry: General Theories and other aspects.Recommanded Product: 65-71-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 11, 1977, Casals, Jose Bou published a patent.Category: pyrimidines The title of the patent was Stable injection potentiated sulfonamide preparations. And the patent contained the following:

Stable injectable potentiated sulfonamide preparations comprise a sulfonamide diethanolamine salt, a sulfonamide potentiator salt, and a solvent mixture of 10-50 parts H2O, 15-30 parts propylene glycol [57-55-6], and 20-40 parts N-methylpyrrolidone [872-50-4]. The solutions have pH 5.5-7.5. For example, 30 mL N-methylpyrrolidone was added to a solution of diaveridin lactate [64191-45-3] (from 4 g diaveridin and 5 g lactic acid) in 10 mL H2O. This solution was added to a solution of sulfafurazole diethanolamine salt (I) [4299-60-9] (from 20 g sulfafurazole) in 20 mL H2O and 20 mL propylene glycol, and the pH was adjusted to 6.7-7.0. Phenylcarbazole (1 mL) was added, and the solution was diluted to 100 mL with propylene glycol, filter-sterilized, and placed in ampuls. The high H2O content decreased the tissue damage at the injection site after i.m. administration. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Category: pyrimidines

The Article related to sulfonamide potentiated injection, sulfafurazole potentiated injection, diaveridin sulfafurazole injection, trimethoprim sulfafurazole injection, Pharmaceuticals: Formulation and Compounding and other aspects.Category: pyrimidines

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On July 7, 1982, Takagishi, Yasushi; Ohsuga, Kiichiro; Ohama, Sadao published a patent.Recommanded Product: 23256-42-0 The title of the patent was Suppositories containing trimethoprim/sulfamethoxazole and a phospholipid. And the patent contained the following:

Antimicrobial pharmaceutical or veterinary compositions suitable for colonic administration comprise sulfamethoxazole-trimethoprim (I-II mixture) [8064-90-2] or their salts as the active ingredients and a phospholipid (0.5-5% by weight) for the purpose of preventing the solidification at the step of mixing I and II with a base material(s) and for solving simultaneously the delay of disintegration. Thus, a suppository containing I 20, II 4, phospholipid (soya lecithin) 2, and Witepsol 74 parts disintegrated after storage at cold and room temperature for 3 mo in 9 and 13 min, resp., compared to 35 min and not even after 60 min, resp., for controls. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 23256-42-0

The Article related to antimicrobial sulfamethoxazole trimethoprim phospholipid, veterinary sulfamethoxazole trimethoprim phospholipid, lecithin sulfamethoxazole trimethoprim suppository, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 2, 2019, Stockum, Werner; Lindhardt, Charlotte published a patent.Related Products of 23256-42-0 The title of the patent was Methods for performing cell culture on solid media containing different cell culture media ingredients. And the patent contained the following:

The present invention relates to methods for performing cell culture by using a solid cell culture media form prepared by a 3D printing process. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Related Products of 23256-42-0

The Article related to performing cell culture solid multilayer media, Biochemical Methods: Culture and Preservation and other aspects.Related Products of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Gackowski, Daniel; Gawronski, Maciej; Kerr, Cassandra; Radivoyevitch, Tomas; Zarakowska, Ewelina; Starczak, Marta; Abakir, Abdulkadir; Ruzov, Alexey; Maciejewski, Jaroslaw P.; Olinski, Ryszard published an article in 2020, the title of the article was Base 5-formylcytosine and 5-hydroxymethyluracil as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome, respectively.Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione And the article contains the following content:

TET2 protein has been implicated in 5-hydroxymethyluracil generation to quantify the extent to which TET2 mutations cause deficiencies in TET2 dioxygenase activity. In the present study, the linkage between various TET2 mutations and 5-hydroxymethylcytosine, 5-formylcytosine, 5-carboxycytosine and 5-hydroxymethyluracil, and linkage between these modifications and myeloid neoplastic disease were characterized. We selected patients with a broad range of different types of TET2 alterations and detected in samples from them a broad spectrum of DNA modifications. Levels of DNA markers of TET2 activity obtained using automated two-dimensional ultra-performance liquid chromatog. tandem mass spectrometry with incorporation of stable isotope-labeled internal standards The results reavealed that the best predictor/marker of TET2 mutations in patients with myeloid malignancies was 5-formylcytosine. Receiver operating characteristic (ROC) curves for predicting TET2 mutated vs. wild-type subjects show that a 5-formylcytosine threshold of 0.204 per 106dN yields a sensitivity of 100% and a specificity of 83%. Disruption of SF3B1 in the K562 cell line resulted in G2/M cell cycle arrest. In conclusion, our results suggested that the anal. of 5-formylcytosine and 5-hydroxymethyluracil are warranted as surrogate markers of TET2 and SF3B1 mutations in myelodysplastic syndrome . The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

The Article related to formylcytosine hydroxymethyluracil tet2 sf3b1 mutation myelodysplastic syndrome, Mammalian Pathological Biochemistry: Oncology and other aspects.Name: 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Nam, Jaehyuk; Jung, Yongseok; Jang, Woo-Dong published an article in 2017, the title of the article was Uracil-bearing poly(2-isopropyl-2-oxazoline): Hg(II)-selective control of its thermoresponsiveness.Related Products of 4433-40-3 And the article contains the following content:

A poly(2-isopropyl-2-oxazoline)-containing mercury ion (Hg2+)-responsive uracil moiety (U-PiPOx-U) was synthesized and it exhibited thermoresponsiveness in its aqueous solution The changes in the UV-visible absorption and thermoresponsiveness of U-PiPOx-U upon the addition of Hg2+ were studied. Selective sensing of Hg2+ was also studied. The experimental process involved the reaction of 5-(Hydroxymethyl)pyrimidine-2,4(1H,3H)-dione(cas: 4433-40-3).Related Products of 4433-40-3

The Article related to uracil bearing polyisopropyloxazoline mercury selective thermoresponsiveness control, Inorganic Analytical Chemistry: Determinations and other aspects.Related Products of 4433-40-3

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia